Home
Clinical Trials
Long-term Anticoagulation in ...

Long-term Anticoagulation in a Patient With Severe Hemophilia A

NCT ID: NCT07314983

Last Updated: 2026-01-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-22

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of \<1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between the bleeding risk associated with anticoagulation and the antithrombotic protection associated with factor VIII deficiency. The advent of new replacement therapies, characterized by FVIII molecules with a prolonged or very prolonged half-life, provides a high level of FVIII coverage (and therefore protection against the risk of bleeding) in patients receiving prophylaxis, thus facilitating the initiation of anticoagulation therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Platelet Function in Patients With Hemophilia A

NCT02093065

Inhibitor Development in Patients With Hemophilia A Undergoing Surgery

NCT01571934

Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity

NCT02911233

Individually Tailored Prophylaxis in Patients With Severe Hemophilia A

NCT00995046

Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells

NCT04805021

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hemophilia A

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (≥ 18 years) with severe hemophilia A
* Absence of written objection in the subject's medical record to the reuse of their data for scientific research purposes.

Exclusion Criteria

\- Subject having expressed objection to the reuse of their data for scientific research

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France

Strasbourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Laurent SATTLER, PharmD

Role: CONTACT

[email protected]

33 3 88 12 75 28

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Laurent SATTLER, PharmD

Role: primary

[email protected]

33 3 88 12 75 28

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9816

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Clinical and Health-related Outcome of rFVIIIFc Prophylaxis

NCT04583930 UNKNOWN

Hemophilia Inhibitor Previously Untreated Patient Study

NCT01652027 COMPLETED

Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia

NCT00178607 COMPLETED

Rituximab to Treat Severe Hemophilia A

NCT00331006 COMPLETED PHASE2

Clot Formation and Clot Stability in Patients With Severe Haemophilia A

NCT00279578 COMPLETED NA

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

NCT01712438 COMPLETED PHASE3

Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

NCT00782470 COMPLETED

A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care

NCT02049099 COMPLETED

Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B

NCT03287999 UNKNOWN

Epidemiology and Immunology of Hemophilia A Inhibitors

NCT00005518 COMPLETED

Multidimensional Assessment of Chronic Pain in Severe Haemophilia A

NCT07096349 RECRUITING

Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia

NCT05804734 COMPLETED

A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor

NCT01800435 COMPLETED PHASE4

Patterns of Hemophilia Care in Assiut Children Patients

NCT05980377 UNKNOWN

Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors

NCT02453542 RECRUITING

Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A

NCT01125813 COMPLETED PHASE3

Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients

NCT02622646 UNKNOWN

Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

NCT02256917 COMPLETED PHASE3

Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A

NCT02035384 COMPLETED

Study Evaluating Inhibitor Specificity in Hemophilia A

NCT00151385 WITHDRAWN PHASE4

Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A

NCT02280265 UNKNOWN NA

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

NCT01561391 COMPLETED PHASE4

Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants

NCT03876301 COMPLETED

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

NCT01181128 COMPLETED PHASE3

Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia

NCT07099313 RECRUITING